• Home
  •  / Palatin Technologies

Palatin Technologies

OverviewSuggest Edit

Palatin Technologies is a biopharmaceutical company, developing targeted, receptor-specific peptide therapeutics for the treatment of various diseases. The Company’s principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder. Its drug development programs also include melanocortin peptide system program, including PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation.

TypePublic
Founded1986
HQCranbury Township, USMap
Websitepalatin.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Sept 2019)18(-5%)
Revenue (FY, 2019)$60.3 M(-10%)
Share Price (Sept 2020)$0.5 (+2%)
Cybersecurity ratingAMore

Key People/Management at Palatin Technologies

Carl Spana

Carl Spana

President and Chief Executive Officer
John K.a. Prendergast

John K.a. Prendergast

Chairman of the Board
Johna Lucas

Johna Lucas

Chief Medical Officer
Stephen T. Wills

Stephen T. Wills

Executive Vice President, Chief Financial Officer and Chief Operating Officer
Robert K. Deveer

Robert K. Deveer

Director
Alan W. Dunton

Alan W. Dunton

Director
Show more

Palatin Technologies Office Locations

Palatin Technologies has an office in Cranbury Township
Cranbury Township, US (HQ)
4b Cedarbrook Dr, Cranbury
Show all (1)

Palatin Technologies Financials and Metrics

Palatin Technologies Revenue

Palatin Technologies's revenue was reported to be $60.30 m in FY, 2019
USD

Net income (Q3, 2020)

(5.4m)

EBIT (Q3, 2020)

(5.7m)

Market capitalization (16-Sept-2020)

116.1m

Closing stock price (16-Sept-2020)

0.5

Cash (31-Mar-2020)

88.9m

EV

27.3m
Palatin Technologies's current market capitalization is $116.1 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

73.7k10.4k13.0m44.7m67.1m60.3m

Revenue growth, %

(100%)

General and administrative expense

5.0m5.1m5.0m5.7m6.2m9.6m8.6m9.7m

R&D expense

13.8m10.5m10.8m24.6m43.1m45.7m32.6m14.9m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

27.2k11.5k24.0k3.8k6.6k4.9m8.0m10.8m26.9m10.6m9.0m34.5k97.4k20.6k

General and administrative expense

1.1m1.0m1.3m1.1m1.0m1.1m1.0m980.1k1.2m1.1m1.4m1.1m1.2m1.4m1.4m1.2m1.3m4.8m1.5m1.6m2.4m2.0m2.1m1.8m1.8m2.4m2.1m

R&D expense

2.3m2.7m4.7m2.3m2.4m2.9m3.4m2.6m2.2m2.9m4.3m7.6m10.6m11.3m10.7m11.2m8.1m9.1m14.2m6.0m7.1m3.6m3.0m3.9m3.1m3.3m3.6m

Operating expense total

3.4m3.7m6.1m3.4m3.4m4.0m4.5m3.6m3.4m4.0m5.7m8.7m11.8m12.6m12.1m12.4m9.4m13.8m15.7m7.7m9.5m5.7m5.1m5.8m5.0m5.7m5.7m
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

3.8m19.2m12.2m27.3m8.0m40.2m38.0m43.5m

Accounts Receivable

27.6k5.5m15.1m60.3m

Prepaid Expenses

532.0k332.3k156.4k1.9m1.0m513.7k637.3k

Inventories

1.4m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

14.9m11.9m8.8m33.5m32.9m23.5m18.6m16.7m16.7m17.8m42.7m36.7m47.5m32.0m21.8m8.9m12.1m54.5m39.7m35.0m25.7m32.6m24.7m19.8m96.7m91.5m88.9m

Accounts Receivable

1.1m16.6k31.4k38.0k3.0m4.7m9.4m104.2k97.4k118.0k

Prepaid Expenses

403.1k814.7k673.4k851.8k343.9k488.2k251.7k300.2k414.6k473.6k1.5m2.0m1.8m1.7m1.5m1.0m838.3k1.1m940.0k1.3m701.5k420.6k535.1k697.2k597.9k656.6k675.4k

Current Assets

15.3m13.8m9.5m34.3m33.2m30.0m22.6m18.5m17.1m18.3m47.2m38.7m49.3m35.1m24.6m11.3m14.3m61.2m50.3m36.2m26.4m33.1m25.2m20.5m97.4m92.2m89.6m
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(17.3m)(20.9m)(13.9m)(17.7m)(51.7m)(13.3m)24.7m35.8m

Depreciation and Amortization

949.5k111.8k111.9k117.6k43.1k33.1k56.6k58.6k

Accounts Payable

(202.0k)43.8k(77.4k)845.2k(392.6k)837.5k672.3k(1.7m)

Cash From Operating Activities

(15.5m)(13.6m)(12.2m)(13.4m)(47.4m)12.9m1.7m(21.8m)
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(3.4m)(6.0m)(12.0m)(10.5m)(12.1m)(16.1m)(4.5m)(8.1m)(9.6m)794.7k3.6m(5.6m)(12.4m)(25.7m)(38.4m)(13.1m)(23.1m)(26.6m)10.6m13.6m12.9m(5.7m)(10.7m)(16.5m)(4.5m)(9.7m)(15.1m)

Depreciation and Amortization

255.0k501.1k737.1k27.5k54.8k82.4k27.2k56.6k84.3k27.6k55.2k86.8k10.7k22.2k33.2k7.6k15.3k22.9k14.6k28.9k42.6k14.0k27.9k43.5k18.3k36.5k50.8k

Accounts Payable

(160.7k)83.7k61.0k26.7k189.9k438.5k652.2k(47.7k)93.0k300.1k1.2m2.1m2.2m1.3m676.8k445.5k4.0m529.3k482.3k(847.6k)(757.7k)(1.1m)(1.6m)(1.7m)(447.0k)(369.6k)1.1m

Cash From Operating Activities

(4.0m)(7.0m)(10.1m)(4.7m)(5.3m)(8.6m)(2.0m)(6.2m)(7.7m)5.7m1.4m(3.9m)(9.4m)(23.4m)(33.7m)(6.6m)(17.7m)25.8m1.4m(1.6m)(8.8m)(5.5m)(11.0m)(14.8m)54.8m49.9m47.4m
show all
USDQ1, 2012

Financial Leverage

1.1 x
Show all financial metrics

Palatin Technologies Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

Learn more about about our premium products
SecurityScorecard logo

Palatin Technologies Online and Social Media Presence

Palatin Technologies's Trends

Embed Graph

Palatin Technologies News and Updates

August 05, 2020

Palatin Technologies, Inc. Announces Completion of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease

CRANBURY, N.J., Aug. 5, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today...
July 08, 2020

Palatin Technologies, Inc. Announces Reinitiation of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease

CRANBURY, N.J., July 8, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today...
June 29, 2020

Palatin Technologies Announces Adjournment of Annual Meeting of Stockholders

CRANBURY, N.J., June 29, 2020 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) announced that its 2020 Annual Meeting of Stockholders that convened on June 25, 2020 has been adjourned until July 23, 2020 at 9:00 a.m. Eastern Daylight Time to solicit additional...
June 23, 2020

Palatin Technologies to Develop PL8177 as a Potential Treatment for COVID-19 and Associated Lung Complications

CRANBURY, N.J., June 23, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced it is...
February 19, 2020

Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643

CRANBURY, N.J., Feb. 19, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today...
February 11, 2020

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights

CRANBURY, N.J., Feb. 11, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, whose...
Show more

 Palatin Technologies Frequently Asked Questions

  • When was Palatin Technologies founded?

    Palatin Technologies was founded in 1986.

  • Who are Palatin Technologies key executives?

    Palatin Technologies's key executives are Carl Spana, John K.a. Prendergast and Johna Lucas.

  • How many employees does Palatin Technologies have?

    Palatin Technologies has 18 employees.

  • What is Palatin Technologies revenue?

    Latest Palatin Technologies annual revenue is $60.3 m.

  • What is Palatin Technologies revenue per employee?

    Latest Palatin Technologies revenue per employee is $3.4 m.

  • Who are Palatin Technologies competitors?

    Competitors of Palatin Technologies include Albumedix, Acticor Biotech and Retrophin.

  • Where is Palatin Technologies headquarters?

    Palatin Technologies headquarters is located at 4b Cedarbrook Dr, Cranbury, Cranbury Township.

  • Where are Palatin Technologies offices?

    Palatin Technologies has an office in Cranbury Township.

  • How many offices does Palatin Technologies have?

    Palatin Technologies has 1 office.